---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-23-000025"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T05:56:12.067150+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jazz Q1 EPS $1.04, adj. $3.95; rev $893M (+10%); Xywav +49%, guidance affirmed

## Summary
- GAAP net income $69.4M ($1.04 EPS) vs $1.6M ($0.03) in 1Q22; non-GAAP adj. net income $285.3M ($3.95 EPS) vs $261.9M ($3.73).
- Total revenue $892.8M (+10% YoY); neuroscience $654.0M (+7%), oncology $228.9M (+16%).
- Xywav net sales $277.8M (+49%), Epidiolex $188.9M (+20%), Rylaze $85.9M (+58%).
- FY 2023 guidance affirmed: rev $3.675-3.875B; GAAP EPS $5.90-$7.90; non-GAAP adj. EPS $16.90-$17.85.
- Pipeline: zanidatamab ASCO June 2, JZP150 PTSD Phase 2 top-line late 2023, suvecaltamide ET Phase 2b 1H24.

## SEC filing metadata
- accession: 0001232524-23-000025
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000025/0001232524-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000025/jazz-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-23-000025
- JSON: https://secwatch.observer/filing/0001232524-23-000025.json
- Plain text: https://secwatch.observer/filing/0001232524-23-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.